Ventyx Biosciences, Inc. Stock
Stocks
VTYX
US92332V1070
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-03-03 EST
|
5-day change | 1st Jan Change | ||
| 14.00 USD | +0.14% |
|
-.--% | +55.04% |
| 03-05 | Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from S&P Pharmaceuticals Select Industry Index | CI |
| 03-05 | Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from S&P Global BMI Index | CI |
| Market Cap | 644M 578M 534M 484M 905M 61.21B 916M 6.4B 2.54B 32.08B 2.42B 2.37B 102B | P/E 2023 |
-0.75x | P/E 2024 | -1.11x |
|---|---|---|---|---|---|
| Enterprise Value | 402M 361M 333M 302M 565M 38.2B 572M 4B 1.59B 20.03B 1.51B 1.48B 63.5B | EV / Sales 2023 |
-
| EV / Sales 2024 | - |
| Free-Float |
99.78% | Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript: Ventyx Biosciences, Inc.
| 1 day | +0.14% | ||
| Current year | +55.04% |
| Current year | 7.08 |  | 25 |
| 1 year | 6.38 | | 25 |
| 3 years | 0.78 | | 25 |
| 5 years | 0.78 | | 47.25 |
| 10 years | 0.78 | | 47.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jonathan Haug
PSD | President | - | 2026-03-03 |
Snehal Naik
CTO | Chief Tech/Sci/R&D Officer | - | 2024-01-31 |
| Corporate Secretary | - | 2026-03-03 |
| Director | Title | Age | Since |
|---|---|---|---|
Jonathan Haug
BRD | Director/Board Member | - | 2026-03-03 |
| Director/Board Member | - | 2026-03-03 | |
Sherry Davis
BRD | Director/Board Member | - | 2026-03-03 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/4/26 | Issuer sale | Chief Technology Officer | 441,000 | 0.6145% | ||
| 3/4/26 | Issuer sale | Chief Financial Officer | 287,013 | 0.4000% | ||
| 3/4/26 | Issuer sale | Chief Technology Officer | 1,806,148 | 2.5169% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.14% | -.--% | +140.96% | -7.35% | 1B | |
| -3.10% | -3.43% | +36.29% | +67.69% | 65.28B | |
| +0.33% | +7.26% | +11.51% | +77.95% | 54.57B | |
| +0.16% | +3.69% | +8.39% | +101.27% | 53.59B | |
| -0.75% | +1.38% | +24.89% | +50.91% | 45.03B | |
| -1.30% | -4.80% | +16.05% | +114.76% | 42.17B | |
| +1.26% | -5.26% | +221.12% | +900.64% | 39.42B | |
| -0.74% | -4.84% | +14.53% | +44.45% | 32.71B | |
| -2.70% | -7.34% | +23.17% | +0.36% | 24.01B | |
| +1.11% | +15.18% | +60.27% | +49.33% | 26.5B | |
| Average | -0.57% | +1.81% | +55.72% | +140.00% | 38.43B | |
| Weighted average by Cap. | -0.73% | +1.72% | +43.54% | +154.82% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | - | - |
| Net income | -193M -173M -160M -145M -271M -18.33B -274M -1.92B -761M -9.61B -724M -709M -30.47B | -135M -121M -112M -102M -190M -12.83B -192M -1.34B -533M -6.73B -507M -496M -21.33B |
| Net Debt | -240M -215M -199M -180M -337M -22.77B -341M -2.38B -946M -11.93B -900M -881M -37.85B | -242M -217M -201M -182M -340M -23B -344M -2.41B -955M -12.06B -909M -890M -38.23B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- VTYX Stock
Select your edition
All financial news and data tailored to specific country editions
